Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En plattformforsøk for gramnegative blodstrømsinfeksjoner (BALANCE+)

5. november 2026 oppdatert av: Dr. Nick Daneman, Sunnybrook Health Sciences Centre

BALANCE+: En plattformforsøk for gramnegative blodstrømsinfeksjoner

BALANCE+ is a perpetual multiple domain randomized controlled platform trial to evaluate various treatment strategies for Gram-negative bloodstream infections (GN BSIs). Each domain addresses critical questions in the management of GN BSIs, aiming to refine treatment strategies, enhance patient outcomes, and reduce antimicrobial resistance.

The initial vanguard pilot RCT (NCT05893147) started on 29 August 2023 and has successfully completed the pilot phase on 24-Apr-2024. All patients enrolled in the vanguard phase are part of the main platform trial.

Studieoversikt

Detaljert beskrivelse

BALANCE+ is an adaptive platform trial evaluating multiple treatment options in patients admitted to the hospital due to Gram negative bloodstream infections (BSIs). It focuses on both cross-cutting and subgroup-specific questions, using an open-label, pragmatic design embedded in routine care.

BALANCE+ addresses the significant health concern of BSIs, which have high morbidity and mortality rates, exacerbated by the global public health threat of antimicrobial resistance (AMR). With rising resistance rates and limited new drug development, effective treatment strategies for BSIs remain under-researched.

BALANCE+ follows the BALANCE trial, which evaluated duration of antibiotic treatment, and aims to further investigate critical questions in managing Gram-negative BSIs. This platform trial will explore various aspects of BSI treatment, including antibiotic de-escalation, oral antibiotic choices, central line management, treatment of specific pathogens, and the necessity of follow-up blood cultures.

BALANCE+ is using Bayesian methods without a fixed sample size. Interim analyses will occur after every 1000th patient in each domain, and then for every 200th patient thereafter. The trial will stop if futility or superiority thresholds are met, or if a domain reaches its ceiling sample size (2500 patients for most domains and 4000 for the beta-lactam versus non-beta-lactam domain) without meeting a stopping threshold.

A vanguard pilot trial involving over 150 patients at 9 hospitals across Canada confirmed the feasibility of the BALANCE+ trial. The main trial will include patients from the vanguard pilot phase since there has been no major change in the overall study design and domains. The adaptive design allows for interim analyses and adjustments by adding or removing domains as per the statistical analysis plan, enhancing the trial's efficiency and relevance.

Studietype

Intervensjonell

Registrering (Antatt)

2500

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • New South Wales
      • Kogarah, New South Wales, Australia, 2217
        • Rekruttering
        • St George Hospital
        • Hovedetterforsker:
          • Richard Sullivan
        • Ta kontakt med:
        • Underetterforsker:
          • Pam Konecny
        • Ta kontakt med:
          • Rachael Roberts, Research Coordinator
      • New Lambton, New South Wales, Australia
        • Rekruttering
        • John Hunter Hospital
        • Ta kontakt med:
        • Ta kontakt med:
          • Telefonnummer: +61 2 4921 3000
        • Hovedetterforsker:
          • Joshua Davis
    • Queensland
      • Herston, Queensland, Australia, 4006
        • Rekruttering
        • Royal Brisbane and Women's Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Patrick Harris, Infectious Disease Physician
      • Redcliffe, Queensland, Australia
        • Rekruttering
        • Redcliffe Hospital
        • Hovedetterforsker:
          • Kevin O'Callaghan
        • Ta kontakt med:
      • Sunshine Coast, Queensland, Australia
        • Rekruttering
        • Sunshine Coast University Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gururaj Nagaraj
    • Victoria
      • Clayton, Victoria, Australia
        • Rekruttering
        • Monash Medical Center
        • Hovedetterforsker:
          • Ben Rogers
        • Ta kontakt med:
    • Western Australia
      • Murdoch, Western Australia, Australia
        • Rekruttering
        • Fiona Stanley Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Edward Raby
      • Murdoch, Western Australia, Australia
        • Rekruttering
        • St John of God
        • Ta kontakt med:
        • Hovedetterforsker:
          • Adrian Regli
    • Alberta
      • Calgary, Alberta, Canada
      • Calgary, Alberta, Canada
        • Rekruttering
        • Peter Lougheed Centre
        • Hovedetterforsker:
          • Ranjani Somayaji
        • Ta kontakt med:
      • Calgary, Alberta, Canada
        • Rekruttering
        • South Health Campus
        • Hovedetterforsker:
          • Ranjani Somayaji
        • Ta kontakt med:
      • Calgary, Alberta, Canada
        • Rekruttering
        • Foothills Hospital
        • Ta kontakt med:
          • Ranjani Somayaji, MD
      • Edmonton, Alberta, Canada
        • Rekruttering
        • University of Alberta
        • Ta kontakt med:
        • Hovedetterforsker:
          • Wendy Sligl
    • British Columbia
      • Surrey, British Columbia, Canada
        • Rekruttering
        • Surrey Memorial Hospital
        • Hovedetterforsker:
          • Kevin Afra
        • Ta kontakt med:
      • Vancouver, British Columbia, Canada
        • Rekruttering
        • Vancouver General Hospital
        • Hovedetterforsker:
          • Jennifer Grant
        • Ta kontakt med:
    • Manitoba
      • Winnipeg, Manitoba, Canada
        • Rekruttering
        • Health Sciences Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sylvain Lother
      • Winnipeg, Manitoba, Canada
        • Rekruttering
        • St. Boniface Hospital
        • Hovedetterforsker:
          • Terry Wuerz
        • Ta kontakt med:
      • Winnipeg, Manitoba, Canada
        • Rekruttering
        • Grace Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gloria Vazquez-Grande
    • New Brunswick
      • Fredericton, New Brunswick, Canada
        • Rekruttering
        • Dr. Everett Chalmers Regional Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Rosa Rossana
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada
        • Rekruttering
        • Eastern Regional Health Authority
        • Ta kontakt med:
          • Peter Daley, MD
    • Ontario
      • Mississauga, Ontario, Canada
        • Rekruttering
        • Trillium Health Partners - Mississauga Hospital
        • Ta kontakt med:
        • Ta kontakt med:
          • Mobina Khurram
        • Hovedetterforsker:
          • Christopher Graham
      • North York, Ontario, Canada
        • Rekruttering
        • Humber River Health system
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ian Brasg
      • North York, Ontario, Canada
        • Rekruttering
        • North York General Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pavani Das
      • Ottawa, Ontario, Canada
        • Rekruttering
        • The Ottawa Hospital
        • Ta kontakt med:
          • Derek McFadden, MD
      • St. Catharines, Ontario, Canada
        • Rekruttering
        • Niagara Health System
        • Ta kontakt med:
          • Aidan Findlater, MD
      • Toronto, Ontario, Canada
        • Rekruttering
        • University Health Network
        • Ta kontakt med:
          • Bryan Coburn, MD
      • Toronto, Ontario, Canada, M4N3M5
        • Rekruttering
        • Sunnybrook Health Sciences Centre
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Rob A Fowler, MD
        • Hovedetterforsker:
          • Nick Daneman, MD
      • Toronto, Ontario, Canada
        • Rekruttering
        • Michael Garron Hospital
        • Ta kontakt med:
          • Christopher Kandel, MD
      • Toronto, Ontario, Canada
        • Rekruttering
        • Mount Sinai Hospital
        • Ta kontakt med:
          • Michael Fralick, PhD
      • Toronto, Ontario, Canada
        • Rekruttering
        • St. Joseph's Health Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kevin Schwartz
    • Quebec
      • Laval, Quebec, Canada
        • Rekruttering
        • Hôpital de la Cité de la Santé
        • Ta kontakt med:
        • Hovedetterforsker:
          • Marco Bergevin
        • Underetterforsker:
          • Stéphanie Castonguay
        • Underetterforsker:
          • Olivier Haeck
        • Underetterforsker:
          • Esther Simoneau
        • Underetterforsker:
          • Marios Roussos
        • Underetterforsker:
          • Natalie Rivest
        • Underetterforsker:
          • Tuyen Nguyen
      • Laval, Quebec, Canada
        • Rekruttering
        • CHU de Québec - Université Laval
        • Ta kontakt med:
        • Hovedetterforsker:
          • Francois Lauzier
        • Underetterforsker:
          • Julie Bestman-Smith
      • Montreal, Quebec, Canada
        • Rekruttering
        • Montreal General Hospital- McGill
        • Ta kontakt med:
        • Hovedetterforsker:
          • Todd C Lee
        • Hovedetterforsker:
          • Emily Mcdonald
      • Montreal, Quebec, Canada
        • Rekruttering
        • Royal Victoria Hospital- McGill
        • Ta kontakt med:
        • Hovedetterforsker:
          • Emily McDonald
        • Hovedetterforsker:
          • Todd C Lee
      • Sherbrooke, Quebec, Canada
        • Rekruttering
        • Université de Sherbrooke
        • Ta kontakt med:
          • François Lamontagne, MD
      • Trois-Rivières, Quebec, Canada, G8Z 3R9
        • Rekruttering
        • Centre hospitalier affilié universitaire régional (CHAUR)
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jean-François Naud
    • Cundinamarca
      • Chía, Cundinamarca, Colombia
        • Rekruttering
        • Universidad de La Sabana
        • Ta kontakt med:
        • Hovedetterforsker:
          • Luis Felipe Reyes Velasco
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israel
        • Rekruttering
        • Sheba Medical Center
        • Hovedetterforsker:
          • Dafna Yahav
        • Ta kontakt med:
    • Auckland
      • Auckland, Auckland, New Zealand, 2025
        • Rekruttering
        • Middlemore Hospital
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Susan Morpeth, Clinical Microbiologist
        • Underetterforsker:
          • Michael Trent Herdman, Specialist Registrar
      • Takapuna, Auckland, New Zealand, 0622
    • Wellington Region
      • Newtown, Wellington Region, New Zealand, 6021
        • Rekruttering
        • Wellington Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Maxim Bloomfield
        • Underetterforsker:
          • Paul Young

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 sekund til 130 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

PLATFORM INCLUSION CRITERIA

Platform Inclusion Criteria:

  • admitted to a participating hospital
  • positive blood culture with Gram negative (GN) bacterium

Platform Exclusion Criteria:

  • patient's goals of care are for palliation with no active treatment
  • moribund patient, not expected to survive > 72 hours
  • previously enrolled in the platform trial
  • not eligible for any domain at the time of screening

DOMAIN SPECIFIC INCLUSION AND EXCLUSION CRITERIA

  1. De-escalation versus no de-escalation domain

    Inclusion Criteria

    - included in BALANCE+ platform

    Exclusion Criteria

    • receiving an empiric antibiotic regimen at the time of blood culture finalization to which the GN pathogen(s) are not sensitive

    • arbapenem-non-susceptible

    • no de-escalation option due to any or all of:

      • antimicrobial resistance
      • allergies
      • medical contraindications
      • drug-drug interaction risk
      • other relevant reason
    • patients with a suspected or proven polymicrobial source of infection

    • > 24 hours since index blood culture susceptibility results finalization

  2. Beta-lactam versus non-beta-lactam oral/enteral treatment domain

    Inclusion Criteria

    • included in BALANCE+ platform
    • initially treated with intravenous antibiotics, but clinical team transitioning patient to oral/enteral antibiotic within 7 days of starting treatment

    Exclusion Criteria

    • enrolled in an arm of another BALANCE+ platform domain which limits the use of oral/enteral therapy:

    • no-de-escalation arm (patients in the no de-escalation arm cannot be randomized into this domain unless they are ready for discharge home, in which case de-escalation is allowable to oral agents at discharge)

    • no non-beta-lactam options due to any or all of:

      • resistance
      • allergies
      • medical contraindications
      • drug-interaction risk
      • other relevant reason
    • no beta-lactam options due to any or all of:

      • resistance
      • allergies
      • medical contraindications
      • drug-interaction risk
      • other relevant reason
    • pregnancy

    • already received >24 hours of oral antibiotics after index blood culture finalization

  3. Central vascular catheter replacement domain

    Inclusion Criteria

    • included in BALANCE+ platform
    • has an indwelling central vascular catheter that was already in place within the 48-hour period before the onset of bloodstream infection (i.e. is not a new catheter placed within 48 hours of the onset of infection)

    Exclusion Criteria

    • patient has no ongoing need for a central vascular catheter

    • patient has definite indication for central vascular catheter removal

    • ongoing septic shock with definite/probable line source o concomitant S. aureus bacteremia

      • concomitant candidemia
    • local suppurative signs (severe redness, warmth, pain, swelling or fluctuance/collection) necessitating catheter removal, or other clinical evidence of infected line (e.g. imaging/echocardiographic findings)

  4. Low-risk AmpC domain

    Inclusion Criteria

    • included in BALANCE+ platform
    • positive blood culture with GN bacterium, of the following species: i. Serratia spp. ii Morganella spp. iii Providencia spp. iv Proteus spp. other than P.mirabilis
    • organism is susceptible to ceftriaxone

    Exclusion Criteria

    - severe allergy to beta-lactams (e.g., type 4 hypersensitivity reaction or DRESS)

    • baseline phenotypic non-susceptiblity to ceftriaxone
    • more than 1 calendar day beyond availability of susceptibility results
  5. Follow up blood culture domain

    Inclusion Criteria

    - included in BALANCE+ platform

    Exclusion Criteria

    • patient died or discharged from hospital prior to day 4
    • blood culture already collected by the treating team at day 4±1
    • >5 days since index positive blood culture collection
    • definite indication for repeat blood culture testing o concomitant S. aureus bacteremia o concomitant Candidemia o clinical suspicion for infective endocarditis
  6. 4 day versus 7-day antibiotic duration

    Inclusion Criteria • improving clinical trajectory, based on meeting all of these criteria by the 4th calendar day of adequate antibiotics:

    o temperature 35.0ºC-37.9ºC

    o not on vasopressors

    o FiO2 ≤ 50%

    Exclusion Criteria

    • Has not undergone successful source control (if required) before completing 4th calendar day of adequate antibiotics

    • Neutropenia (<0.5 × 10⁹/L)

    • solid organ or bone marrow transplantation
    • suspected or documented deep-seated infection requiring prolonged antibiotics

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Deeskalering VS Ingen Deeskalering

No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result). De-escalation is only allowed within 7 days if patient is being discharged from hospital.

De-escalation group: switched to narrower spectrum antibiotic (based on spectrum scale specified in protocol).

Aktiv komparator: Orale beta-laktamer VS Orale Ikke-beta-laktamer

Beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime.

Non beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.

Aktiv komparator: Sentralt karkateterretensjon VS Utskifting av sentralvaskulær kateter

Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 3 calendar days from blood culture finalization (removal must happen within that time; replacement can occur after that time point)

Central vascular catheter retention: the catheter will not be changed and will be retained until it is non functional or no longer needed.

Aktiv komparator: Cephalosporin VS Carbapenem for lavrisiko AmpC-organismer

Cephalosporin (ceftriaxone) at standard doses

Carbapenem (Meropenem or Ertapenem) at standard doses

Aktiv komparator: Routine follow-up blood culture VS No routine follow-up blood culture

Enrollment to the domain has been completed.

Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.

No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria

Aktiv komparator: 4-day versus 7-day antibiotic duration

The shorter duration arm will receive 4 days of adequate antibiotics. The longer duration arm will receive 7 days of adequate antibiotics.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Desirability of Outcome Ranking (DOOR) Ordinal Scale which incorporates death, reinfection, readmission, and for some domains incorporates a tie-breaker of new antimicrobial resistance (AMR).
Tidsramme: 90 days

The primary outcome for each domain will use a Desirability of Outcome Ranking (DOOR) ordinal scale in which patients are categorized into the following mutually exclusive categories, ranked from best to worst status:

  1. Alive with no reinfection or readmission.
  2. Alive with reinfection OR readmission.
  3. Alive with reinfection AND readmission.
  4. Dead

For the 4 antibiotic-related domains (the de-escalation versus no de-escalation domain, the beta-lactam versus non-beta-lactam domain, the low risk AmpC domain, and the 4 versus 7 day duration domain) there will be an additional tie-breaker within ordinal levels 1, 2 and 3 based on whether there was new detection of antimicrobial resistance (AMR).

90 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
30 dagers dødelighet
Tidsramme: 30 dager
30 dager
90-dagers dødelighet
Tidsramme: 90 dager
90 dager
60 dagers dødelighet
Tidsramme: 60 dager
60 dager
90 dager forårsaker alle reinnleggelse
Tidsramme: 90 dager
90 dager
90-dagers AMR-kolonisering/infeksjon
Tidsramme: 90 dager
90 dager
90-dagers Clostridioides difficile-infeksjon (CDI)
Tidsramme: 90 dager
90 dager
90-dagers re-infeksjon
Tidsramme: 90 dager
90 dager
Additional Secondary Outcomes for Follow up blood culture domain
Tidsramme: 90 days
  • total duration of antibiotic therapy
  • hospital length of stay
90 days
Additional Secondary Outcomes for De-escalation versus no de-escalation Domain
Tidsramme: 90 days
  • change in total microbiome diversity between the day of randomization and discharge (or day 30 if earlier)
  • net change in resistome AMR burden between the day of randomization and discharge (or day 30 if earlier).
90 days
Additional Secondary Outcomes for Beta-lactam versus non-beta-lactam domain
Tidsramme: 90 days
  • antibiotic-related allergic reaction
  • antibiotic-related adverse event
90 days
Additional Secondary Outcomes for Central vascular catheter replacement versus retention domain
Tidsramme: 90 days
  • pneumothorax or thoracotomy tube insertion related to vascular catheter
  • clinically important bleeding
  • line associated thrombus
  • persistent bacteremia >5d from initial index culture
  • secondary bloodstream infection with new bacterial or fungal organism
90 days
Additional Secondary Outcomes for Low-risk AmpC domain
Tidsramme: 90 days
  • isolation of ESBL producing organism or third generation cephalosporin resistant Gram negative organism
  • isolation of a carbapenem-resistant organism
90 days
Additional domain-specific secondary outcomes in 4-day versus 7-day antibiotic duration
Tidsramme: 90 days
  • antibiotic-related allergic reaction

  • antibiotic-related (non-allergic) adverse event (grade 4+ or 3+ with treatment change)

  • microbiome/resistome sub-study

    • change in total microbiome diversity (Shannon diversity index) between the day of randomization and day 30
    • change in total microbiome diversity (Shannon diversity index) between the day of randomization and day 7
    • net change in resistome AMR burden between the day of randomization and day 30
    • change in total microbiome diversity (Shannon diversity index) between the day of randomization and day 7
90 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Nick Daneman, MD, Sunnybrook Health Sciences Centre
  • Hovedetterforsker: Rob Fowler, MD, Sunnybrook Health Sciences Centre

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. april 2024

Primær fullføring (Antatt)

1. april 2027

Studiet fullført (Antatt)

1. april 2028

Datoer for studieregistrering

Først innsendt

25. juli 2024

Først innsendt som oppfylte QC-kriteriene

31. juli 2024

Først lagt ut (Faktiske)

5. august 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 4369-1

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere